GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TMS Co 4891.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

131

0.00%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

—

FY2021FY2026

Net income

−¥859.3m

FY2021FY2026

Free cash flow

−¥782.4m

FY2021FY2026

Shareholders' equity

¥2.77bn

FY2021FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021
Revenue————¥1.95bn—
Gross profit−¥314,400−¥3.7m−¥7.0m−¥6.6m¥1.74bn−¥4.1m
Research and development¥548.0m¥621.1m¥607.7m¥292.8m¥103.1m¥603.2m
Operating income−¥836.4m−¥907.8m−¥943.3m−¥520.1m¥1.14bn−¥721.2m
Net income−¥859.3m−¥660.5m−¥960.0m−¥860.9m¥1.08bn−¥722.9m
Diluted earnings per share-18.85-14.52-23.80-22.7632.16-15.86

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021
Total assets¥2.87bn¥3.03bn¥3.55bn¥3.79bn¥2.74bn¥1.21bn
Cash and short-term investments¥2.78bn¥2.92bn¥3.45bn¥3.58bn¥2.60bn¥1.11bn
Total liabilities¥95.0m¥216.8m¥97.7m¥76.2m¥286.8m¥86.4m
Shareholders' equity¥2.77bn¥2.82bn¥3.46bn¥3.71bn¥2.45bn¥1.13bn
Shares outstanding46m45m40m38m33m46m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021
Cash from operations−¥779.9m−¥493.8m−¥822.8m−¥688.4m¥1.26bn−¥737.8m
Capital spending−¥2.5m−¥30.8m−¥3.4m−¥13.7m−¥8.9m−¥499,000
Free cash flow−¥782.4m−¥524.6m−¥826.2m−¥702.1m¥1.25bn−¥738.3m

Latest quarters

By quarter end

Aug 2026May 2026Feb 2026Aug 2025May 2025Feb 2025Nov 2024Aug 2024
Gross profit—−¥16,000−¥41,000−¥229,000−¥33,000−¥145,000−¥89,000−¥234,000
Operating income−¥392.3m−¥188.6m−¥203.7m−¥197.9m−¥274.0m−¥251.5m−¥204.1m−¥229.0m
Net income−¥393.5m−¥189.2m−¥204.3m−¥201.1m−¥286.3m¥22.1m−¥204.8m−¥230.2m
Diluted earnings per share-8.63-4.15-4.48-4.42-6.290.49-5.08-5.71
Total assets¥2.51bn¥2.51bn¥2.66bn¥3.12bn¥3.21bn¥3.03bn¥2.92bn¥3.09bn
Cash and short-term investments¥2.46bn¥2.46bn¥2.63bn¥3.08bn¥3.18bn¥2.92bn¥2.80bn¥3.01bn
Shareholders' equity¥2.36bn¥2.41bn¥2.58bn¥2.99bn¥3.09bn¥2.82bn¥2.79bn¥2.99bn

Financial ratios

Data as of 12 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021
Gross margin————89.6%—
Operating margin————58.3%—
Net margin————55.3%—
Return on equity-31.0%-23.5%-27.8%-23.2%43.9%-64.2%
Return on assets-30.0%-21.8%-27.0%-22.7%39.3%-59.6%
Free cash flow yield-14.1%-8.4%-16.8%-14.7%31.4%—
Earnings growth30.1%-31.2%11.5%-179.9%-249.0%—
Current ratio30.46x13.97x36.36x49.46x9.54x14.04x
Debt to equity———0.00x0.00x0.00x
Equity ratio96.7%92.9%97.3%98.0%89.5%92.9%
R&D as a share of sales————5.3%—
Buybacks as a share of market value-0.2%-12.8%-6.6%-13.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Operating income17.2%3.0%—
Net income-0.1%3.5%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022
Price to earnings-7.2-8.9-9.2-8.319.3
Price to sales————10.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.